These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 39418085)

  • 1. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide.
    Jalleh RJ; Plummer MP; Marathe CS; Umapathysivam MM; Quast DR; Rayner CK; Jones KL; Wu T; Horowitz M; Nauck MA
    J Clin Endocrinol Metab; 2024 Oct; ():. PubMed ID: 39418085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions.
    Jalleh RJ; Rayner CK; Hausken T; Jones KL; Camilleri M; Horowitz M
    Lancet Gastroenterol Hepatol; 2024 Oct; 9(10):957-964. PubMed ID: 39096914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
    Kuwata H; Yabe D; Murotani K; Fujiwara Y; Haraguchi T; Kubota S; Kubota-Okamoto S; Usui R; Ishitobi M; Yamazaki Y; Hamamoto Y; Kurose T; Seino Y; Yamada Y; Seino Y
    J Diabetes Investig; 2021 Dec; 12(12):2162-2171. PubMed ID: 34022121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.
    Urva S; Coskun T; Loghin C; Cui X; Beebe E; O'Farrell L; Briere DA; Benson C; Nauck MA; Haupt A
    Diabetes Obes Metab; 2020 Oct; 22(10):1886-1891. PubMed ID: 32519795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like peptide-1 receptor agonists: a narrative review of clinical pharmacology and implications for peri-operative practice.
    Milder DA; Milder TY; Liang SS; Kam PCA
    Anaesthesia; 2024 Jul; 79(7):735-747. PubMed ID: 38740566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception.
    Skelley JW; Swearengin K; York AL; Glover LH
    J Am Pharm Assoc (2003); 2024; 64(1):204-211.e4. PubMed ID: 37940101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-Like Peptide-1 Receptor Agonists Increase Solid Gastric Residue Rates on Upper Endoscopy Especially in Patients With Complicated Diabetes: A Case-Control Study.
    Garza K; Aminpour E; Shah J; Mehta B; Early D; Gyawali CP; Kushnir V
    Am J Gastroenterol; 2024 Jun; 119(6):1081-1088. PubMed ID: 38534127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity.
    Maselli DB; Camilleri M
    Adv Exp Med Biol; 2021; 1307():171-192. PubMed ID: 32077010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists: concerns for delayed gastric emptying and pulmonary aspiration.
    van Zuylen ML; Siegelaar SE; Plummer MP; Deane AM; Hermanides J; Hulst AH
    Br J Anaesth; 2024 Apr; 132(4):644-648. PubMed ID: 38290907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying--preclinical evidence.
    Werner U
    J Diabetes Complications; 2014; 28(1):110-4. PubMed ID: 23992745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Impact of GLP-1 Receptor Agonists on Endoscopic Patient Outcomes in an Ambulatory Setting: A Retrospective Study at a Large Tertiary Center.
    Robalino Gonzaga E; Farooq A; Mohammed A; Chandan S; Fawwaz B; Singh G; Malik A; Zhang Y; Kadkhodayan K
    J Clin Med; 2024 Sep; 13(18):. PubMed ID: 39336890
    [No Abstract]   [Full Text] [Related]  

  • 13. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
    Nauck MA; D'Alessio DA
    Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretin hormones and type 2 diabetes.
    Nauck MA; Müller TD
    Diabetologia; 2023 Oct; 66(10):1780-1795. PubMed ID: 37430117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
    Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
    Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-Like Peptide-1 Agonists and General Anesthesia: Perioperative Considerations and the Utility of Gastric Ultrasound.
    Willson CM; Patel L; Middleton P; Desai M
    Cureus; 2024 Apr; 16(4):e58042. PubMed ID: 38738030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Confounding Factors in the Association Between Glucagon-Like Peptide-1 Receptor Agonist Use and Retained Gastric Contents in Asymptomatic Patients Undergoing Upper Gastrointestinal Endoscopy: A Retrospective Study.
    Elimihele TA; Mangrola AM; Oshomoji O; Wilson NB; Nnamani I; Ashong B; Billings S; Getu DK; Kumar S; Maliakkal B
    Cureus; 2024 Sep; 16(9):e69152. PubMed ID: 39398811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.
    Meier JJ; Kemmeries G; Holst JJ; Nauck MA
    Diabetes; 2005 Jul; 54(7):2212-8. PubMed ID: 15983224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: A review.
    Albèr A; Brønden A; Knop FK
    Diabetes Obes Metab; 2017 Jul; 19(7):915-925. PubMed ID: 28211611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of glucagon-like peptide-1 receptor agonists on gastric mucosal visibility and retained gastric contents during EGD.
    Chapman MB; Norwood DA; Price C; Abdulhadi B; Kyanam Kabir Baig K; Ahmed AM; Peter S; Routman JS; Sánchez-Luna SA; Duggan EW; Mulki R
    Gastrointest Endosc; 2024 Nov; 100(5):923-927. PubMed ID: 38759761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.